Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tardif, J.-C.
Right arrow Articles by Berry, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tardif, J.-C.
Right arrow Articles by Berry, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

From coronary artery disease to heart failure: potential benefits of ivabradine

Jean-Claude Tardif* and Colin Berry

Department of Medicine, Montreal Heart Institute, 5000 Belanger Street, Montreal, Canada H1T 1C8

* Corresponding author. Tel: +1 514 376 3330 ext. 3612, fax: +1 514 593 2500. E-mail address: jean-claude.tardif{at}icm-mhi.org

In addition to the beneficial effects of heart rate reduction for the prevention of angina, a lower heart rate is also associated with a more favourable prognosis in patients with coronary artery disease (CAD). A high resting heart rate is a strong predictor for cardiovascular mortality and morbidity in patients with CAD. Patients with resting heart rate above 77 bpm are also prone to more re-hospitalizations for cardiovascular reasons, independently of major risk factors compared with patients with lower resting heart rates. These issues are clinically important because they support the relevance of testing the effect of lowering heart rate to reduce cardiovascular mortality and morbidity. The value of ivabradine for reduction in hard cardiovascular events in patients with ischaemic heart disease is presently being tested in the ongoing large-scale BEAUTIFUL (morBidity–mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction) study. Also, the prognostic value of heart rate in patients with heart failure and the lack of intrinsic negative inotropic effects of ivabradine have prompted its evaluation in addition to modern multifaceted therapy of heart failure in the Systolic Heart failure treatment with If inhibitor ivabradine Trial (SHIFT). These large-scale clinical trials will help to determine whether the spectrum of patients benefiting from a pure heart rate-reducing agent, such as ivabradine, goes beyond those with angina and whether the clinical benefits are much greater than prevention of angina and extend to reduction in cardiovascular mortality and morbidity.

Key Words: If current • Ivabradine • Myocardial infarction • Stunning • Heart rate • Angina • Atherosclerosis • Heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.